Security
PTCT · PTC THERAPEUTICS, INC.
PTCTNASDAQCommon stockCurrentCIK 1070081Updated Sep 27, 2026
Name history
PTC THERAPEUTICS INC · through Oct 12, 2005
PTCT price & chart
Loading TradingView…
NASDAQ:PTCT on TradingView ↗About the company
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.
In the news
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director ↗
Seeking Alpha
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential ↗
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
Entry into a Material Definitive Agreement
Items 1.01
144/A filing
144 filing
Show 5 more recent filings
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
10-Q filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 2.02, 5.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,898,767,000Source | 1,705,024,000Source | 1,895,698,000Source | 1,705,619,000Source |
| Property, Plant and Equipment, NetUSD | 55,371,000Source | 60,970,000Source | 87,089,000Source | 72,590,000Source |
| GoodwillUSD | 82,341,000Source | 82,341,000Source | 82,341,000Source | 82,341,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 388,753,000Source | 118,794,000Source | 379,497,000Source | 705,891,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 984,648,000Source | 779,709,000Source | 594,001,000Source | 279,834,000Source |
| Inventory, NetUSD | 79,647,000Source | 23,194,000Source | 30,577,000Source | 21,808,000Source |
| Assets, CurrentUSD | 2,273,948,000Source | 1,365,531,000Source | 1,218,629,000Source | 693,785,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 67,309,000Source | 44,087,000Source | 150,491,000Source | 105,658,000Source |
| Operating Lease, Right-of-Use AssetUSD | 80,053,000Source | 56,685,000Source | 91,896,000Source | 102,430,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,104,080,000Source | 2,803,095,000Source | 2,714,253,000Source | 2,052,705,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 80,000Source | 77,000Source | 75,000Source | 72,000Source |
| Additional Paid in CapitalUSD | 2,748,335,000Source | 2,574,611,000Source | 2,466,233,000Source | 2,305,020,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,964,229,000Source | -3,646,873,000Source | -3,283,578,000Source | -2,656,974,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 10,501,000Source | -25,886,000Source | -1,285,000Source | 4,796,000Source |
| Stockholders' Equity Attributable to ParentUSD | -205,313,000Source | -1,098,071,000Source | -818,555,000Source | -347,086,000Source |
| Liabilities and EquityUSD | 2,898,767,000Source | 1,705,024,000Source | 1,895,698,000Source | 1,705,619,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 968,427,000Source | 580,981,000Source | 603,100,000Source | 406,236,000Source |
| Operating Lease, Liability, CurrentUSD | 12,484,000Source | 10,363,000Source | 13,002,000Source | 9,370,000Source |
| Accounts Payable, CurrentUSD | 45,487,000Source | 17,274,000Source | 6,045,000Source | 27,268,000Source |
| Operating Lease, Liability, NoncurrentUSD | 93,583,000Source | 74,947,000Source | 97,627,000Source | 100,860,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 55,905,000Source | 102,834,000Source |
| Other Liabilities, NoncurrentUSD | 13,704,000Source | 21,426,000Source | 141,000Source | 2,641,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | — | — | 55,905,000Source | 102,834,000Source |
| Long-term Debt, Current MaturitiesUSD | 286,631,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 285,412,000Source | 284,213,000Source | 571,722,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 38,815,000Source | 75,663,000Source | 236,590,000Source | 128,836,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 74,547,000Source | 74,615,000Source | 101,636,000Source | 110,333,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 53,896,000Source | -6,164,000Source | 8,183,000Source | 6,668,000Source |
| Deferred Income Tax Expense (Benefit)USD | -3,000Source | -55,912,000Source | -46,930,000Source | -34,276,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 711,196,000Source | -107,688,000Source | -158,418,000Source | -356,654,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -861,984,000Source | 44,182,000Source | -176,737,000Source | 290,181,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 8,860,000Source | 6,502,000Source | 28,438,000Source | 32,016,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 331,094,000Source | 255,866,000Source | 646,400,000Source | 167,952,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 203,018,000Source | 185,032,000Source | 314,359,000Source | 98,707,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 998,334,000Source | 795,316,000Source | 610,284,000Source | 295,925,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,702,000Source | 5,823,000Source | 36,131,000Source | 18,463,000Source |
| Income Taxes Paid, NetUSD | 36,854,000Source | 17,550,000Source | 14,155,000Source | 4,922,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 74,547,000Source | 74,615,000Source | 101,636,000Source | 110,333,000Source |
| Amortization of Debt Issuance CostsUSD | 1,219,000Source | 1,198,000Source | 1,873,000Source | 1,901,000Source |
| Amortization of Intangible AssetsUSD | 24,742,000Source | 60,738,000Source | 222,635,000Source | 116,554,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | -622,000Source | — | — |
| DepreciationUSD | 14,200,000Source | 14,900,000Source | 13,900,000Source | 12,300,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 4,383,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 3,960,000Source | 2,572,000Source | 2,517,000Source | -7,992,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -16,887,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -3,380,000Source | 10,374,000Source | 14,113,000Source | -13,263,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -806,000Source | -80,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | -163,000Source | -345,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -130,000Source | -4,298,000Source | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | 2,179,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -137,558,000Source | — |
| GoodwillUSD | 82,341,000Source | 82,341,000Source | 82,341,000Source | 82,341,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | 159,548,000Source | 217,800,000Source | 33,384,000Source |
| Income Tax Expense (Benefit)USD | 13,975,000Source | 176,000Source | -69,506,000Source | -28,470,000Source |
| Inventory Write-downUSD | 5,200,000Source | 13,200,000Source | 12,500,000Source | 1,700,000Source |
| Net Income (Loss) Attributable to ParentUSD | 682,644,000Source | -363,295,000Source | -626,604,000Source | -559,017,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 682,644,000Source | -363,295,000Source | -626,604,000Source | -559,017,000Source |
| Operating ExpensesUSD | 863,720,000Source | 1,109,350,000Source | 1,377,324,000Source | 1,146,210,000Source |
| Operating Lease, ExpenseUSD | 21,100,000Source | 24,900,000Source | 29,000,000Source | 25,200,000Source |
| Other Nonoperating Income (Expense)USD | -18,086,000Source | 6,544,000Source | 10,130,000Source | -49,207,000Source |
| Proceeds from Stock Options ExercisedUSD | 93,102,000Source | 28,565,000Source | 24,040,000Source | 14,632,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,730,655,000Source | 806,780,000Source | 937,822,000Source | 698,801,000Source |
| Selling, General and Administrative ExpenseUSD | 347,143,000Source | 300,911,000Source | 332,540,000Source | 325,998,000Source |
| Operating Income (Loss)USD | 866,935,000Source | -302,570,000Source | -439,502,000Source | -447,409,000Source |
| Other Nonoperating Income (Expense)USD | -18,086,000Source | 6,544,000Source | 10,130,000Source | -49,207,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 696,619,000Source | -363,119,000Source | -696,110,000Source | -587,487,000Source |
| Income Tax Expense (Benefit)USD | 13,975,000Source | 176,000Source | -69,506,000Source | -28,470,000Source |
| Net Income (Loss) Attributable to ParentUSD | 682,644,000Source | -363,295,000Source | -626,604,000Source | -559,017,000Source |
| Earnings Per Share, BasicUSD per share | 8.58Source | -4.73Source | -8.37Source | -7.79Source |
| Earnings Per Share, DilutedUSD per share | 7.78Source | -4.73Source | -8.37Source | -7.79Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 79,534,290Source | 76,845,055Source | 74,838,392Source | 71,728,634Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 88,311,494Source | 76,845,055Source | 74,838,392Source | 71,728,634Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 24,742,000Source | 60,738,000Source | 222,635,000Source | 116,554,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 4,383,000Source | — |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -16,887,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,249,817,000Source | -598,807,000Source | -784,744,000Source | -591,126,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -152,230,000Source | -166,993,000Source | -129,180,000Source | -90,871,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 682,644,000Source | -363,295,000Source | -626,604,000Source | -559,017,000Source |
| Operating ExpensesUSD | 863,720,000Source | 1,109,350,000Source | 1,377,324,000Source | 1,146,210,000Source |
| Operating Lease, ExpenseUSD | 21,100,000Source | 24,900,000Source | 29,000,000Source | 25,200,000Source |
| Research and Development ExpenseUSD | 455,249,000Source | 534,480,000Source | 666,563,000Source | 651,496,000Source |
Filing attachments
tmb-20260921xex99d1.htm · 8-K · 2026-09-21
Exhibit 99.1 PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - Completion of BLA submission expected in Q4 2026 - WARREN, N.J., Sept. 21, 2026 - PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 - a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.…
Read attachment ↗tmb-20260812xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 tmb-20260812xex99d1.htm EX-99.1 Exhibit 99.1 PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization - - ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile - - BLA submission expected to be …
Read attachment ↗tmb-20260728xex99d1.htm · 8-K · 2026-07-30
EX-99.1 2 tmb-20260728xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue - - Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million - - Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake an…
Read attachment ↗tm2618266d1_ex4-1.htm · 8-K · 2026-06-18
EX-4.1 2 tm2618266d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Execution Version PTC THERAPEUTICS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 18, 2026 0% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. …
Read attachment ↗tm2618041d1_ex99-1.htm · 8-K · 2026-06-16
EX-99.1 2 tm2618041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 - WARREN, N.J., June 15, 2026 - PTC Therapeutics, Inc., (NASDAQ: PTCT) today ann…
Read attachment ↗tmb-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 tmb-20260507xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise - - Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth - - Positive topline results from 24-month interim an…
Read attachment ↗